Portal de Periódicos da CAPES

The Use of Percent Free PSA for Early Detection of Prostate Cancer Minireview

1999; Wiley; Volume: 20; Issue: 4 Linguagem: Inglês

10.1002/j.1939-4640.1999.tb02540.x

2047-2927

Steven R. Potter, THOMAS RECKWTTZ, Alan W. Partin,

Urinary Bladder and Prostate Research

Journal of AndrologyVolume 20, Issue 4 p. 449-453 Free Access The Use of Percent Free PSA for Early Detection of Prostate Cancer Minireview STEVEN R. POTTER, STEVEN R. POTTER Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Search for more papers by this authorTHOMAS RECKWTTZ, THOMAS RECKWTTZ Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Search for more papers by this authorALAN W. PARTIN, Corresponding Author ALAN W. PARTIN Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Correspondence to: Alan W. Partin, M.D., Ph.D., Department of Urology, Johns Hopkins Hospital, 600 North Wolfe St., Baltimore, Maryland 21287.Search for more papers by this author STEVEN R. POTTER, STEVEN R. POTTER Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Search for more papers by this authorTHOMAS RECKWTTZ, THOMAS RECKWTTZ Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Search for more papers by this authorALAN W. PARTIN, Corresponding Author ALAN W. PARTIN Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland.Correspondence to: Alan W. Partin, M.D., Ph.D., Department of Urology, Johns Hopkins Hospital, 600 North Wolfe St., Baltimore, Maryland 21287.Search for more papers by this author First published: 02 January 2013 https://doi.org/10.1002/j.1939-4640.1999.tb02540.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Bangma CH, Kranse R., Blijengerg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Results of a retrospective evaluation of 1726 men. Urology 1995a: 46: 773–778. Bangma CH, Kranse R., Blijengerg BG, Schroder FH. The value of screening tests in the detection of prostate cancer. Retrospective analysis of free/total prostate-specific antigen ratio, age-specific reference ranges, and PSA density. Urology 1995b: 46: 779–784. Bates TS, Reynard JM, Peters TJ, Gingell JC. Determination of prostate volume with transrectal ultrasound: a study of intra-observer and interobserver variation. J Urol 1996; 155: 1299–1300. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A., Richie JP, de Kernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998; 279: 1542–1547. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. J Am Med Assoc 1997: 277: 1452–1455. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigenbased screening. J Am Med Assoc 1993; 270: 948–954. Catalona WJ, Smith DS, Wolfert R., Wang TJ, Rittenhouse H., Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 1995; 274: 1214–1220. Chen YT, Luderer AA, Thiel RP, Carlson G., Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 1996; 47: 518–524. Christensson A., Bjork T., Nilsson O., Dahlen U., Matikainen M. T., Cockett ATK, Abrahamsson P. A., Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100–105. Christensson A., Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755–763. Elgamal AA, Cornillie FJ, van Poppel HP, van de Voorde WM, McCabe R., Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant T1c prostate cancer. J Urol 1996; 156: 1042–1047. Fortunate A., Dorizzi RM, Marchi G., Cocco C., Davini CCA. fPSA/tPSA ratios obtained using nine commercial assays. Clin Chem (Suppl) 1996; 42: 268. Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ. Serum percent free PSA does not predict extraprostatic spread of prostate cancer. Am. J Clin Pathol 1998: 109: 533–539. Jung K., Stephan C., Lein M., Henke W., Schnorr D., Brux B., Schurenkamper P., Loening SA. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996; 42: 1026–1033. Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology 1997; 50: 901–905. Lilja H., Christensson A., Dahlen U., Matikainen MT, Nilsson O., Pettersson K., Lovgren T. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991; 37: 1618–1625. Littrup PJ, Goodman AC. Economic considerations of prostate cancer: the role of detection specificity and biopsy reduction. Cancer (Suppl) 1988: 1987–1993. Luderer AA, Chen Y. T., Soriano TF, Kramp WJ, Carlson G., Cuny C., Sharp T., Smith W., Petteway J., Brawer MK. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187–194. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974–1994. J Urol 1997; 158: 1427–1430. Nixon RG, Meyer SE, Blasé AB, Gold MH, Brawer MK. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998; 160: 420–425. Pannek J., Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E., Partin AW. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159: 449–453. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology (Suppl) 1996a; 48: 55–61. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358–1368. Partin AW, Piantadosi S., Subong EN, Kelley CA, Hortopan S., Chan DW, Wolfert RL, Rittenhouse HG, Carter HB. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate (Suppl) 1996b; 7: 35. Pettersson K., Piironen T., Seppala M., Liukkonen L., Christensson A., Matikainen MT, Suonpaa M., Lovgren T., Lilja H. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA alpha-1-antichymotrypsin complex. Clin Chem 1995; 41: 1480–1488. Prestigiacomo AF, Lilja H., Pettersson K., Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 1996; 156: 350–354. Stenman UH, Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. Complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–226. van Cangh PJ, de Nayer P., Sauvage P., Tombal B., Elsen M., Lorge F., Opsomer R., Wese FX. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate (Suppl) 1996; 7: 30–34. Vashi AR, Wojno KJ, Henricks W., England BA, Vessella RL, Lange PH, Wright GL Jr, Schellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE. Determination of the "reflex range" and appropriate cutpoints for percent free-PSA in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19–27. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol (Suppl) 1998; 159: 5–12. Woodrum D., French C., Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48: 33–39. Volume20, Issue4July‐August 1999Pages 449-453 ReferencesRelatedInformation